All patients
Age < 65y (younger) Age > 65y BRAF mutant BRAF wild type ECOG 0 ECOG 1 Gender, female Gender, male LDH > ULN LDH ≤ULN previous systemic treatment (%) previous systemic treatment NO (%) stage IIIa stage IIIb stage IIIc stage M0/M1A/M1B stage M1C stage M1C (with brain metastasis)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
melanoma (ML), ipilimumab alone vs. ipilimumab alone, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1.19 [1.00; 1.42]
1.19 [1.00 ; 1.42 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 727 NA not evaluable progression or deaths (PFS)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1.12 [0.83; 1.52]
1.12 [0.83 ; 1.52 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 727 NA not evaluable DCRdetailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.84 [0.61; 1.16]
0.84 [0.61 ; 1.16 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 727 NA not evaluable objective responses (ORR)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.76 [0.50; 1.17]
0.76 [0.50 ; 1.17 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 727 NA not evaluable TRAE (any grade)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.42 [0.31; 0.57]
0.42 [0.31 ; 0.57 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.37 [0.25; 0.54]
0.37 [0.25 ; 0.54 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable TRAE leading to death (grade 5)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.50 [0.09; 2.75]
0.50 [0.09 ; 2.75 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable TRAE leading to discontinuation (any grade)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.51 [0.36; 0.72]
0.51 [0.36 ; 0.72 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable TRAE leading to discontinuation (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.44 [0.30; 0.66]
0.44 [0.30 ; 0.66 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.50 [0.02; 15.01]
0.50 [0.02 ; 15.01 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable Colitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.46 [0.21; 1.04]
0.46 [0.21 ; 1.04 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.54 [0.31; 0.95]
0.54 [0.31 ; 0.95 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable Endocrine disorders TRAE (grade 3-4) detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.43 [0.19; 1.01]
0.43 [0.19 ; 1.01 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable Eye disorders TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 2.01 [0.07; 60.22]
2.01 [0.07 ; 60.22 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.25 [0.01; 5.57]
0.25 [0.01 ; 5.57 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.55 [0.34; 0.88]
0.55 [0.34 ; 0.88 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.25 [0.01; 5.57]
0.25 [0.01 ; 5.57 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.40 [0.08; 2.07]
0.40 [0.08 ; 2.07 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable Hypersensitivity TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.17 [0.01; 3.33]
0.17 [0.01 ; 3.33 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable Hypophysitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.70 [0.26; 1.85]
0.70 [0.26 ; 1.85 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.50 [0.02; 15.01]
0.50 [0.02 ; 15.01 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable Increase AST TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.12 [0.02; 0.99]
0.12 [0.02 ; 0.99 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.16 [0.04; 0.73]
0.16 [0.04 ; 0.73 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable Increased lipase level TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.50 [0.02; 15.01]
0.50 [0.02 ; 15.01 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.25 [0.01; 5.57]
0.25 [0.01 ; 5.57 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable Maculopapular rash TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.50 [0.02; 15.01]
0.50 [0.02 ; 15.01 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable Nervous system disorders TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.12 [0.01; 2.36]
0.12 [0.01 ; 2.36 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable Pancreatitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.50 [0.02; 15.01]
0.50 [0.02 ; 15.01 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable Pancytopenia TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.50 [0.02; 15.01]
0.50 [0.02 ; 15.01 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable Pericarditis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.50 [0.02; 15.01]
0.50 [0.02 ; 15.01 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.25 [0.01; 5.57]
0.25 [0.01 ; 5.57 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.12 [0.01; 2.36]
0.12 [0.01 ; 2.36 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable Polymyalgia Rheumatica TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 2.01 [0.07; 60.22]
2.01 [0.07 ; 60.22 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable Pruritic rash TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 2.01 [0.07; 60.22]
2.01 [0.07 ; 60.22 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable Pruritus TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1.01 [0.14; 7.18]
1.01 [0.14 ; 7.18 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable Rash TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.40 [0.08; 2.07]
0.40 [0.08 ; 2.07 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.12 [0.01; 2.36]
0.12 [0.01 ; 2.36 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.71 [0.22; 2.27]
0.71 [0.22 ; 2.27 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable Thyroiditis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.50 [0.02; 15.01]
0.50 [0.02 ; 15.01 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable Uveitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 2.01 [0.07; 60.22]
2.01 [0.07 ; 60.22 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-22 21:16 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 2,283,284,70,235,285,68,127,128,286,69,129
- treatments: 329,558
